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Tumor cells go with the flow
L
ike the proverbial donkey that follows the 
carrot, tumor cells follow chemical attractants. 
Unlike the donkey, however, the tumor cells 
even make their own carrots, according to a report 
by Melody Swartz, Jacqueline Shields, Mark 
Fleury (École Polytechnique Fédérale de Lausanne, 
Lausanne, Switzerland), and colleagues.
The group was interested in how tumor cells 
migrate to lymphatic vessels—the ﬁ   rst step in 
malignancy for most carcinomas. Migrating tumor 
cells express receptors for attractants that lym-
phatics normally produce to lure immune cells. 
Shields et al. now show that tumor cells don’t need 
to rely on lymphatics to make the attractants they 
follow; they can produce the chemicals themselves.
A tumor cell would make no progress, how-
ever, if its secreted attractants were all around it. 
The group therefore predicted that the ﬂ   ow of 
tissue ﬂ   uids toward draining lymphatics concen-
trates the attractants downstream, ensuring that 
they always dangle alluringly in front of the 
tumor cell. Computer modeling of this flow-
induced migration supported their prediction. 
The authors then mimicked the ﬂ  uid dynamics 
and 3D structure of tumor tissue in culture. They 
found that blocking the attractant receptors on 
tumor cells prevented the cells from moving in the 
direction of the ﬂ  ow and prevented the reorgani-
zation of actin ﬁ  laments to the leading edge that is 
necessary for migration. The amount of attractants 
secreted by different tumor cells correlated with 
the strength of their self-mobilization and with their 
metastatic potential in vivo.
It’s not yet clear how this new paradigm of au-
tonomous signal–following activity will be applicable 
to cancer therapy, although the results suggest that 
blocking a tumor’s secreted chemokines may help 
prevent its spread. Swartz also envisages one far-out 
surgical possibility: the replacement of a tumor with 
a kind of sponge to reverse the direction of ﬂ  ow in 
the tissue and chemoattractively mop-up remaining 
metastatic cells from the tumor’s locality.
Reference: Shields, J., et al. 2007. Cancer Cell. 
11:526–538.
R
everting adult dopamine-secreting 
neurons to a more youthful state 
might slow or stop the progression 
of Parkinson’s disease (PD), report Savio 
Chan, James Surmeier, and colleagues 
(Northwestern University, Chicago, IL).
The movement defects that characterize 
PD are caused by the death of dopaminergic 
neurons in a part of the brain called the sub-
stantia nigra pars compacta (SNc). SNc neu-
rons have a pacemaking ability that ensures 
the regular release of small pulses of dopa-
mine needed to maintain brain function.
Unlike other dopaminergic neurons, 
those in the SNc depend on calcium 
channels for pacemaking activity. Accord-
ing to Surmeier, however, mice that lack 
these calcium channels have no noticeable 
motor control defi   cits. His group now 
shows that the pacemaking activity of 
these mutant SNc neurons is unaffected.
SNc neurons in the mutant mice car-
ried on pacemaking by instead relying on 
sodium channels. Sodium channels were 
normally responsible for pacemaking only 
in young mice. As the neurons aged, 
sodium channels took over the pacemaking 
duties. Neurons from the mice lacking 
calcium channels thus continued to use 
the juvenile pacemaking strategy.
The group wondered whether they 
might revert wild-type adult SNc neurons 
to a similar juvenile state by simply 
blocking the calcium channels. Treating 
SNc neurons with a known calcium 
channel inhibitor, called isradipine, ini-
tially stopped pacemaking activity. After 
several hours of treatment, however, the 
pacemaking activity returned, now re-
sembling that of juvenile neurons.
Evidence suggests that rising calcium 
levels inside SNc neurons might cause cell 
death in PD. The team found that isradi-
pine reduced the loss of SNc neurons and 
prevented the development of motor def-
icits in a mouse model of PD.
Isradipine is a member of a class of 
drugs called dihydropyridines that are 
used to treat hypertension and stroke. 
Retrospective analysis of patient treatment 
data suggests that dihydropyridines reduce 
the incidence of PD. The fact the drug is 
approved for human use means that its 
effi  cacy in preventing the progression of 
PD could be tested immediately.
Reference: Chan, C.S., et al. 2007. Nature. 
doi:10.1038/nature05865.
A cancer cell under ﬂ  ow 
sits tight with uniform 
actin (green) if it can’t 
see its own chemical 
cues (bottom).



































Could rejuvenating neurons protect against Parkinson’s?